StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > IR

<< Previous

Bullboard Posts

Next >>

Comment by brad129on Nov 20, 2020 12:31pm

89 Views

Post# 31941366

RE:RE:RE:IR

hopefully it closes by end of month at the offering price, then we will rebound a bit

Str8Shuter wrote: Thanks Brad. So, according to the Short Form Prospectus, the PP could close as late as Jan. 17, 2021. In the big picture, that's certainly not very long to wait, versus the prospects of waiting for a CC following the Q4 report that is due by the end of March, 2021. More opportunity for longs to accumulate shares from impatient traders/investors. GLTA!

brad129 wrote: I got a reply thank you Rebecca, a conference call will happen after close of PP.